<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The histiocytoses are <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disorders</z:e> of antigen-processing phagocytic or antigen-presenting cells </plain></SENT>
<SENT sid="1" pm="."><plain>Allogeneic bone marrow transplantation (BMT) can be curative of these disorders </plain></SENT>
<SENT sid="2" pm="."><plain>We report a series of five children with <z:mpath ids='MPATH_653'>Langerhans cell histiocytosis</z:mpath> (n=2) or <z:e sem="disease" ids="C0024291" disease_type="Disease or Syndrome" abbrv="">hemophagocytic lymphohistiocytosis</z:e> (n=3), who received allogeneic BMT with a total body irradiation (TBI)-containing regimen (TBI, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>) at our institution between 1995 and 2000 </plain></SENT>
<SENT sid="3" pm="."><plain>One of these patients received <z:chebi fb="0" ids="28901">busulfan</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and <z:chebi fb="0" ids="4911">etoposide</z:chebi> for the first of two BMTs </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> grafts except one (a matched sibling-donor graft) were T-cell-depleted grafts from unrelated donors </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> received <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GvHD) prophylaxis; the recipient of the matched sibling graft also received <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Three patients engrafted at a median of 24 days after transplantation </plain></SENT>
<SENT sid="7" pm="."><plain>The patient who did not receive TBI experienced primary graft failure and <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>After the TBI-containing conditioning regimen was given, a second transplant engrafted on day +17 </plain></SENT>
<SENT sid="9" pm="."><plain>One patient with concurrent <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> died of toxicity on day +33 without evidence of engraftment </plain></SENT>
<SENT sid="10" pm="."><plain>No <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> GvHD was observed </plain></SENT>
<SENT sid="11" pm="."><plain>Four patients survive disease-free, a median of 63 months after transplantation, <z:hpo ids='HP_0000001'>all</z:hpo> with Lansky performance scores of 100 </plain></SENT>
<SENT sid="12" pm="."><plain>We conclude that a conditioning regimen containing TBI but not <z:chebi fb="0" ids="4911">etoposide</z:chebi> is effective in allogeneic BMT for children with histiocytic diseases </plain></SENT>
</text></document>